Background: The prevalent theory concerning the pathogenesis of chronic obstructive pulmonary disease (COPD) is of an imbalance between oxidants and antioxidants in the lung. It has recently been reported that the production of peroxynitrite, an extremely potent oxidant, is increased in the airways of patients with COPD. A study was undertaken of the imbalance between the levels of nitrogen oxides and antioxidant activity against peroxynitrite in the airways of patients with COPD. Methods: Sputum induction was performed in 30 patients with COPD and 15 normal control subjects. Levels of nitrogen oxides, percentage of neutrophils, and interleukin 8 (IL-8) levels were measured in sputum samples, and peroxynitrite inhibitory activity was assayed by monitoring rhodamine formation. Results: Nitrite and nitrate levels in induced sputum were significantly higher in patients with COPD than in normal controls (949 (133) µM v 621 (89) µM, p<0.001). In contrast, peroxynitrite inhibitory activity in induced sputum was significantly lower in patients with COPD than in normal controls (47.4 (12.7)% v 92.9 (3.9)%, p<0.001). There was a negative correlation between nitrite and nitrate levels and peroxynitrite inhibitory activity in induced sputum (r=-0.775, p<0.001). Peroxynitrite inhibitory activity was also significantly correlated with forced expiratory volume in 1 second (FEV 1 ) % predicted (r=0.539, p=0.004), FEV 1 /FVC (r=0.512, p=0.006), and carbon monoxide transfer factor (TLCO) (r=0.486, p=0.009). Moreover, there was a significant negative correlation between peroxynitrite inhibitory activity and the degree of neutrophilic inflammation (percentage of neutrophils: r=-0.754, p<0.001; IL-8 levels: r=-0.497, p=0.007). Conclusions: Reduced peroxynitrite inhibitory activity and increased levels of nitrogen oxides are found in induced sputum from patients with COPD. An imbalance in nitrogen oxides and antioxidant defence may contribute to the pathogenesis of COPD.
C
hronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world, the prevalence of which is directly related to the prevalence of cigarette smoking. The current theory of the pathogenesis of COPD is an imbalance between oxidants and antioxidants in the lung. 1 This theory proposes that increased numbers of neutrophils and macrophages, activated by cigarette smoke, produce large amounts of oxidants which cause lung destruction.
Peroxynitrite is formed by the reaction of nitric oxide (NO) with superoxide anion. 2 In many pathological conditions including airway inflammation, simultaneous cellular production of superoxide anion and NO may occur, potentially leading to continuous formation of peroxynitrite. Peroxynitrite is an extremely potent oxidant that can cause lipid peroxidation, DNA damage, and alterations in protein function in vitro. 3 It also activates matrix metalloproteinases released from neutrophils and macrophages which are capable of degrading all the components of the extracellular matrix of lung parenchyma and may cause emphysematous change. 4 A previous study showed that the levels of nitrogen oxides in breath condensate were higher in patients with COPD than in control subjects. 5 Moreover, patients with COPD have an increased number of neutrophils in the airways which produce numerous free radicals, causing the oxidation of part of NO into peroxynitrite. 6 This is consistent with our previous demonstration of high levels of nitrite and nitrate in the sputum of patients with clinically stable COPD. 7 These findings may be related to enhanced peroxynitrite stress in COPD. However, little is known about the antioxidant activity against peroxynitrite in the airways of patients with COPD. It is likely that the thin layer of epithelial lining fluid (ELF) may provide antioxidant protection against peroxynitrite and serve as a front line defence for airway epithelial cells. 8 9 The major antioxidants in ELF are based on thiols which may function as antioxidants against peroxynitrite in the respiratory tract. We have therefore measured total antioxidant activity against peroxynitrite to examine the physiological effects of peroxynitrite in the airways of patients with COPD and to determine whether there is an imbalance between levels of nitrogen oxides and antioxidant activity against peroxynitrite in the airways of these patients.
METHODS

Subjects
Thirty patients with COPD who satisfied the American Thoracic Society criteria 10 were randomly enrolled from the respiratory outpatient clinic of our institution. They had a history of former smoking (>20 pack years) and irreversible airflow limitation (reversibility <10% predicted forced expiratory volume in 1 second (FEV 1 ) after 200 µg inhaled salbutamol). Their regular medication consisted of theophylline and an inhaled anticholinergic drug, but none had received oral or inhaled corticosteroids. They received no medication during the spirometric study and sputum induction. All patients were clinically stable and none had a history of respiratory infection for at least 4 weeks before the study. Fifteen healthy lifelong non-smoking volunteers of mean age 58.5 years with no history of lung disease (FEV 1 99.5%) formed a control group.
All subjects gave their written informed consent for participation in the study which was approved by the ethics committee of Osaka City University.
Sputum induction and processing
Spirometric tests were performed before inhalation of 200 µg salbutamol via a metered dose inhaler. All subjects were instructed to wash their mouth thoroughly with water. They then inhaled 3% saline at room temperature, nebulised via an ultrasonic nebuliser (NE-U12, Omron Co, Tokyo, Japan) at maximum output. They were encouraged to cough deeply at 3 minute intervals thereafter. The spirometric tests were repeated after sputum induction. If the FEV 1 fell, the subjects were required to wait until it returned to the baseline value. The sputum sample diluted with phosphate buffer solution (PBS) containing dithiothreitol (final concentration 1 mmol/ l) was then centrifuged at 400g for 10 minutes and the cell pellet was resuspended. Total cell counts were performed with a haemocytometer and slides were made by using a cytospin (Cytospin 3; Shandon, Tokyo, Japan) and stained with May-Grunwald-Giemsa stain for differential cell counts. The supernatant was stored at -70°C for subsequent assay for interleukin 8 (IL-8), nitrite, and nitrate levels.
The IL-8 concentration was measured using an enzyme immunoassay kit (Amersham, UK). Nitrite and nitrate levels in induced sputum were assayed colorimetrically after the Griess reaction as previously described. 11 200 µl of the sputum sample or standard was deproteinated by adding 20 µl NaOH (1.0 mol/l at 4°C; Wako Chemical Co, Osaka, Japan) and 30 µl ZnSO 4 (1.3 mol/l at 4°C; Wako Chemical Co). Samples were mixed and allowed to stand on ice for 15 minutes. After centrifugation (5 minutes at 4°C, 2600g), 100 µl of supernatant was mixed with 5 × 10 -2 units nitrate reductase (Sigma Chemical Co), 20 µl of 0.2 mol/l N-tris (hydroxymethyl) methylamino enthanesulphonic acid (pH 7.0, Sigma Chemical Co), and 20 µl of 0.5 mol/l sodium formate (Wako Chemical Co). After anaerobic incubation at room temperature for 20 minutes, 1.0 ml water was added to the samples and nitrite was assayed in supernatants obtained by centrifugation (5 minutes, 260g). Deproteinated samples or standards (200 µl) were mixed with 20 µl of 1% sulfanilamide (Sigma Chemical Co) in 15% phosphoric acid (Wako Chemical Co). After 10 minutes, 20 µl of 0.1% N-(1-naphthyl) ethylenediamine (Sigma Chemical Co) was added and the absorption at 540 nm was determined. We chose to use the sol phase of sputum for the measurement of peroxynitrite inhibitory activity to avoid the potential confounding influence of DTT, as described in our recent study. 12 The sol phase was obtained by ultracentrifuging the remaining portion of the sputum sample at 60 000g for 60 minutes at 4°C. This was allocated and stored at -70°C for subsequent assay for peroxynitrite inhibitory activity.
All subjects produced an adequate specimen of sputum; a sample was considered adequate if the patient was able to expectorate at least 2 ml of sputum and if, on differential cell counting, the slides contained <10% squamous cells.
Measurement of peroxynitrite inhibitory activity
Working solutions of peroxynitrite (Wako Pure Chemical Industries Ltd, Osaka, Japan) were prepared by dilution in 0.1N NaOH just before use as 10 -2 mol/l solutions and further dilutions were made in PBS. The peroxynitrite concentration was determined spectrophotometrically by measuring the absorption at 302 nm (eM=1670 M -1 cm -1
). Peroxynitrite readily oxidises dihydrorhodamine-123. 13 A standard curve of oxidising activity of dihydrorhodamine-123 to rhodamine was constructed using peroxynitrite. Peroxynitrite inhibitory activity was assayed by monitoring rhodamine formation at 500 nm in reaction mixtures containing 200 µl sputum sample, 1.3 ml dihydrorhodamine-123 diluted with PBS (pH 7.4), and 500 µl peroxynitrite for 30 minutes at 37°C. 14 15 Peroxynitrite inhibitory activity was assayed in at least triplicate, and our recent data supported the specificity of this assay system for peroxynitrite. 16 
Statistical analysis
All values are presented as mean (SD). Differences between groups are presented as mean differences with 95% confidence intervals (CI). Student's t test and Mann-Whitney U test were used to compare group means, and differences in variance were tested using the F test. The significance of correlations was evaluated by determining Spearman rank correlation coefficients. A p value of <0.05 was considered significant.
RESULTS
The clinical characteristics of the 30 patients with COPD and 15 age matched normal controls are shown in table 1. All patients with COPD had significant airflow obstruction and decreased levels of TLCO. The percentage of neutrophils and Nitrite and nitrate levels in induced sputum were significantly higher in patients with COPD than in normal controls (949 (133) µM v 621 (89) µM; mean difference -328 µM, 95% CI of difference -404 to -251, p<0.001; fig 1A) . In contrast, peroxynitrite inhibitory activity in induced sputum was significantly lower in patients with COPD than in normal controls (47.4 (12.7)% v 92.9 (3.9)%; mean difference 45.5%, 95% CI of difference 38.8 to 52.4%, p<0.001; fig 1B) , and there was a negative correlation between nitrite and nitrate levels and peroxynitrite inhibitory activity in induced sputum (r=-0.775, p<0.001; fig 2) . Peroxynitrite inhibitory activity was also significantly correlated with FEV 1 % predicted (r=0.539, p=0.004), FEV 1 /FVC (r=0.512, p=0.006), and TLCO (r=0.486, p=0.009; fig 3) . Moreover, there was a significant negative correlation between peroxynitrite inhibitory activity and the percentage of neutrophils in induced sputum (r=-0.754, p<0.001; fig 4) , and a negative correlation was also found between peroxynitrite inhibitory activity and the concentration of IL-8 in induced sputum (r=-0.497, p=0.007; fig 5) .
DISCUSSION
In the present study peroxynitrite inhibitory activity was assayed by monitoring rhodamine formation. The oxidation of dihydrorhodamine-123 to rhodamine is mediated by peroxynitrite but not by superoxide anion, H 2 O 2 , or NO. Using this method, we found that peroxynitrite inhibitory activity in induced sputum was significantly lower in patients with COPD than in normal controls, and that its activity was correlated with FEV 1 , FEV 1 /FVC, and TLCO. We also found that peroxynitrite inhibitory activity was inversely correlated with the percentage of neutrophils and IL-8 levels in induced sputum in patients with COPD. IL-8 is a cytokine synthesised by various cells including macrophages and neutrophils, and a potent activator of neutrophils. IL-8 induces superoxide anion release from neutrophils in vitro, and intravenous administration of IL-8 in vivo has been reported to induce accumulation of neutrophils in the lung. 17 The expression of IL-8 by various cells in the airways may therefore be critically important in the pathogenesis of COPD. In an earlier study we found that IL-8 levels were significantly higher in patients with COPD than in normal controls, and that IL-8 levels were correlated with the degree of annual decline in FEV 1 in COPD. 18 Moreover, a previous report suggested that airway obstruction and rapid decline in lung function are associated with an increased number of neutrophils in the sputum of smokers. 19 Although prevailing theories for the pathogenesis of COPD have focused on smoking induced production of proteolytic enzymes and oxidants from neutrophils stimulated by IL-8, we found that neutrophilic inflammation was inversely correlated with antioxidant activity against peroxynitrite in the airways of patients with COPD.
Because oxidants play a pronounced role in cigarette smoke induced lung damage, the status of pulmonary antioxidant defence mechanisms assumes paramount importance. However, there is limited information on the antioxidant defences of ELF in smokers and even less for patients with COPD. Moreover, a notable inconsistency exists, and the findings are difficult to compare because of the different designs of the various studies. One study found that cigarette smoking was associated with decreased plasma ascorbate, β-carotene, and vitamin E levels. 20 In addition, vitamin E levels were lower in the lung lavages of young asymptomatic smokers. 21 On the other hand, a number of studies have reported increased antioxidants in cigarette smokers-for example, levels of vitamins C and E were higher in the plasma of cigarette smokers than in non-smokers. 22 Additional endogenous mechanisms may increase antioxidant levels in certain smokers. In this regard, certain smokers had increased glutathione (GSH) and GSH peroxidase activities in their ELF compared with nonsmokers. 23 Thus, there are apparent discrepancies between these studies of antioxidants in ELF.
Airway inflammation seems to play an important role in the pathogenesis of COPD, and it has been shown that the production of superoxide anion and NO by airway inflammatory cells is increased in patients with COPD. 24 The existing evidence suggests that peroxynitrite is formed in the respiratory tract of these patients, although the cellular source of peroxynitrite in the airways of patients with COPD is unclear. A previous study showed that the production of peroxynitrite was increased in airway macrophages and neutrophils in patients with COPD compared with normal control subjects. 25 On the other hand, the reaction of peroxynitrite with airway thiols (RSH) is associated with oxidation of RSH to the corresponding disulfide (RSSR). The method used in this study therefore evaluates the reduced form antioxidants against peroxynitrite. Indeed, it is important to emphasise that local antioxidant defences in patients with COPD is mediated by only the reduced form antioxidants. It seems likely that a balance exists between peroxynitrite generation and antioxidant defences to maintain normal airway function. When the balance is shifted towards increased peroxynitrite generation, the reduced form antioxidants are diminished and therefore the airways have markedly increased susceptibility to peroxynitrite. We have clearly shown that reduced peroxynitrite inhibitory activity is likely to reflect the increases in nitrogen oxides in the airways of patients with COPD.
The novel aspect of this investigation is the finding of reduced peroxynitrite inhibitory activity and increased levels of nitrogen oxides in induced sputum in patients with COPD. This imbalance in nitrogen oxides and antioxidant defence may contribute to the pathogenesis of COPD. 
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